학술논문
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
Document Type
article
Author
Hai-Dong Zhu; Hai-Liang Li; Ming-Sheng Huang; Wei-Zhu Yang; Guo-Wen Yin; Bin-Yan Zhong; Jun-Hui Sun; Zhi-Cheng Jin; Jian-Jian Chen; Nai-Jian Ge; Wen-Bin Ding; Wen-Hui Li; Jin-Hua Huang; Wei Mu; Shan-Zhi Gu; Jia-Ping Li; Hui Zhao; Shu-Wei Wen; Yan-Ming Lei; Yu-Sheng Song; Chun-Wang Yuan; Wei-Dong Wang; Ming Huang; Wei Zhao; Jian-Bing Wu; Song Wang; Xu Zhu; Jian-Jun Han; Wei-Xin Ren; Zai-Ming Lu; Wen-Ge Xing; Yong Fan; Hai-Lan Lin; Zi-Shu Zhang; Guo-Hui Xu; Wen-Hao Hu; Qiang Tu; Hong-Ying Su; Chuan-Sheng Zheng; Yong Chen; Xu-Ya Zhao; Zhu-Ting Fang; Qi Wang; Jin-Wei Zhao; Ai-Bing Xu; Jian Xu; Qing-Hua Wu; Huan-Zhang Niu; Jian Wang; Feng Dai; Dui-Ping Feng; Qing-Dong Li; Rong-Shu Shi; Jia-Rui Li; Guang Yang; Hai-Bin Shi; Jian-Song Ji; Yu-E Liu; Zheng Cai; Po Yang; Yang Zhao; Xiao-Li Zhu; Li-Gong Lu; Gao-Jun Teng; for the CHANCE001 Investigators
Source
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)
Subject
Language
English
ISSN
2059-3635
Abstract
Abstract There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT (combination group, n = 376) or TACE monotherapy (monotherapy group, n = 450) were included from January 2018 to May 2021. The primary endpoint was progression-free survival (PFS) according to modified RECIST. The secondary outcomes included overall survival (OS), objective response rate (ORR), and safety. We performed propensity score matching approaches to reduce bias between two groups. After matching, 228 pairs were included with a predominantly advanced disease population. Median PFS in combination group was 9.5 months (95% confidence interval [CI], 8.4–11.0) versus 8.0 months (95% CI, 6.6–9.5) (adjusted hazard ratio [HR], 0.70, P = 0.002). OS and ORR were also significantly higher in combination group (median OS, 19.2 [16.1–27.3] vs. 15.7 months [13.0–20.2]; adjusted HR, 0.63, P = 0.001; ORR, 60.1% vs. 32.0%; P